GlassScriptPhysician profile
Ossama M Lashin
NPI 1851507586
$21,247.89
in general payments reported to CMS, 2019-2025
17 companies · $9,397 in 2025
The $9,397 reported for 2025 was more than what 90% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $664 · 2020: $282 · 2021: $98.43 · 2022: $307 · 2023: $4,068 · 2024: $6,432 · 2025: $9,397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,000 · Food and Beverage: $4,668 · Travel and Lodging: $3,161 · Honoraria: $3,060 · Education: $7.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,000.00 |
| Food and Beverage | $4,667.70 |
| Travel and Lodging | $3,161.33 |
| Honoraria | $3,060.00 |
| Education | $7.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $10,201.31 | 2019-2025 | Tepezza |
| Siemens Medical Solutions USA, INC. | $4,800.00 | 2025 | |
| Horizon Therapeutics Plc | $3,858.09 | 2023 | Tepezza |
| Abbott Laboratories | $695.01 | 2019-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $374.90 | 2019-2021 | |
| Lilly USA, LLC | $299.31 | 2019-2025 | Mounjaro, Zepbound |
| Tandem Diabetes Care, INC. | $208.59 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Novo Nordisk INC | $170.49 | 2022-2025 | Rybelsus, Ozempic |
| Ascendis Pharma Endocrinology INC | $162.41 | 2025 | Yorvipath |
| Xeris Pharmaceuticals, INC. | $97.07 | 2025 | Recorlev |
| Abbvie INC. | $91.05 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $90.64 | 2022 | |
| Insulet Corporation | $86.94 | 2019 | |
| Corcept Therapeutics | $33.13 | 2024 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.38 | 2019-2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $25.90 | 2019 | |
| Ascensia Diabetes Care US INC. | $21.67 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ossama Lashin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.